Indium-111-photofrin-II scintillation scan

T. C. Origitano, S. M. Karesh, O. H. Reichman, R. E. Henkin, M. J. Caron, R. E. Wharen, James E Boggan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Photodynamic therapy is under intense investigation as an adjuvant treatment for malignant glial tumors of the central nervous system. Photofrin-II (HpD-II) is currently the most actively investigated photosensitizing agent. A crucial issue regarding the safe and efficacious usage of HpD-II-based photodynamic therapy is the individual in vivo kinetics of tumor uptake and retention, compared with normal brain clearance. The optimal time for photoactivation of sensitized tumor must be known to ensure a high target-to-nontarget ration, resulting in the maximal tumor destruction while preserving normal brain. Our laboratory developed a radionuclide scan based on 111indium (111In)-labeled HpD-II to evaluate HpD-II localization and clearance noninvasively within a canine model of intracerebral gliosarcoma. Synthesis of the 111In-HpD-II complex in > 90% yield is achieved by a simple, rapid labeling method. Radiochemical purity and stability were verified by high-performance liquid chromatography. Using the canine model of intracerebral gliosarcoma, we followed the uptake of 111In-HpD-II in tumors with serial scintillation scanning. Localization of the tumor by 111In-HpD-II has been verified by contrast-enhanced computed tomographic scan followed by gross and histological examination of the enhancing brain region. Total body biodistribution of 111In-HpD-II at various times after injection has been evaluated. The ratio of uptake in tumor compared with surrounding brain peaked at 72 hours after injection. The knowledge of regional distribution and concentration of a photosensitizing agent within a tumor mass and surrounding brain allows for the most efficacious timing and localization of a photoactivating source.

Original languageEnglish (US)
Pages (from-to)547-556
Number of pages10
JournalNeurosurgery
Volume24
Issue number4
StatePublished - 1989
Externally publishedYes

Fingerprint

Dihematoporphyrin Ether
Indium
Gliosarcoma
Neoplasms
Brain
Photosensitizing Agents
Photochemotherapy
Canidae
Central Nervous System Neoplasms
Injections
Neuroglia
Radioisotopes
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Origitano, T. C., Karesh, S. M., Reichman, O. H., Henkin, R. E., Caron, M. J., Wharen, R. E., & Boggan, J. E. (1989). Indium-111-photofrin-II scintillation scan. Neurosurgery, 24(4), 547-556.

Indium-111-photofrin-II scintillation scan. / Origitano, T. C.; Karesh, S. M.; Reichman, O. H.; Henkin, R. E.; Caron, M. J.; Wharen, R. E.; Boggan, James E.

In: Neurosurgery, Vol. 24, No. 4, 1989, p. 547-556.

Research output: Contribution to journalArticle

Origitano, TC, Karesh, SM, Reichman, OH, Henkin, RE, Caron, MJ, Wharen, RE & Boggan, JE 1989, 'Indium-111-photofrin-II scintillation scan', Neurosurgery, vol. 24, no. 4, pp. 547-556.
Origitano TC, Karesh SM, Reichman OH, Henkin RE, Caron MJ, Wharen RE et al. Indium-111-photofrin-II scintillation scan. Neurosurgery. 1989;24(4):547-556.
Origitano, T. C. ; Karesh, S. M. ; Reichman, O. H. ; Henkin, R. E. ; Caron, M. J. ; Wharen, R. E. ; Boggan, James E. / Indium-111-photofrin-II scintillation scan. In: Neurosurgery. 1989 ; Vol. 24, No. 4. pp. 547-556.
@article{44702991f84045099411d88e2cac8725,
title = "Indium-111-photofrin-II scintillation scan",
abstract = "Photodynamic therapy is under intense investigation as an adjuvant treatment for malignant glial tumors of the central nervous system. Photofrin-II (HpD-II) is currently the most actively investigated photosensitizing agent. A crucial issue regarding the safe and efficacious usage of HpD-II-based photodynamic therapy is the individual in vivo kinetics of tumor uptake and retention, compared with normal brain clearance. The optimal time for photoactivation of sensitized tumor must be known to ensure a high target-to-nontarget ration, resulting in the maximal tumor destruction while preserving normal brain. Our laboratory developed a radionuclide scan based on 111indium (111In)-labeled HpD-II to evaluate HpD-II localization and clearance noninvasively within a canine model of intracerebral gliosarcoma. Synthesis of the 111In-HpD-II complex in > 90{\%} yield is achieved by a simple, rapid labeling method. Radiochemical purity and stability were verified by high-performance liquid chromatography. Using the canine model of intracerebral gliosarcoma, we followed the uptake of 111In-HpD-II in tumors with serial scintillation scanning. Localization of the tumor by 111In-HpD-II has been verified by contrast-enhanced computed tomographic scan followed by gross and histological examination of the enhancing brain region. Total body biodistribution of 111In-HpD-II at various times after injection has been evaluated. The ratio of uptake in tumor compared with surrounding brain peaked at 72 hours after injection. The knowledge of regional distribution and concentration of a photosensitizing agent within a tumor mass and surrounding brain allows for the most efficacious timing and localization of a photoactivating source.",
author = "Origitano, {T. C.} and Karesh, {S. M.} and Reichman, {O. H.} and Henkin, {R. E.} and Caron, {M. J.} and Wharen, {R. E.} and Boggan, {James E}",
year = "1989",
language = "English (US)",
volume = "24",
pages = "547--556",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Indium-111-photofrin-II scintillation scan

AU - Origitano, T. C.

AU - Karesh, S. M.

AU - Reichman, O. H.

AU - Henkin, R. E.

AU - Caron, M. J.

AU - Wharen, R. E.

AU - Boggan, James E

PY - 1989

Y1 - 1989

N2 - Photodynamic therapy is under intense investigation as an adjuvant treatment for malignant glial tumors of the central nervous system. Photofrin-II (HpD-II) is currently the most actively investigated photosensitizing agent. A crucial issue regarding the safe and efficacious usage of HpD-II-based photodynamic therapy is the individual in vivo kinetics of tumor uptake and retention, compared with normal brain clearance. The optimal time for photoactivation of sensitized tumor must be known to ensure a high target-to-nontarget ration, resulting in the maximal tumor destruction while preserving normal brain. Our laboratory developed a radionuclide scan based on 111indium (111In)-labeled HpD-II to evaluate HpD-II localization and clearance noninvasively within a canine model of intracerebral gliosarcoma. Synthesis of the 111In-HpD-II complex in > 90% yield is achieved by a simple, rapid labeling method. Radiochemical purity and stability were verified by high-performance liquid chromatography. Using the canine model of intracerebral gliosarcoma, we followed the uptake of 111In-HpD-II in tumors with serial scintillation scanning. Localization of the tumor by 111In-HpD-II has been verified by contrast-enhanced computed tomographic scan followed by gross and histological examination of the enhancing brain region. Total body biodistribution of 111In-HpD-II at various times after injection has been evaluated. The ratio of uptake in tumor compared with surrounding brain peaked at 72 hours after injection. The knowledge of regional distribution and concentration of a photosensitizing agent within a tumor mass and surrounding brain allows for the most efficacious timing and localization of a photoactivating source.

AB - Photodynamic therapy is under intense investigation as an adjuvant treatment for malignant glial tumors of the central nervous system. Photofrin-II (HpD-II) is currently the most actively investigated photosensitizing agent. A crucial issue regarding the safe and efficacious usage of HpD-II-based photodynamic therapy is the individual in vivo kinetics of tumor uptake and retention, compared with normal brain clearance. The optimal time for photoactivation of sensitized tumor must be known to ensure a high target-to-nontarget ration, resulting in the maximal tumor destruction while preserving normal brain. Our laboratory developed a radionuclide scan based on 111indium (111In)-labeled HpD-II to evaluate HpD-II localization and clearance noninvasively within a canine model of intracerebral gliosarcoma. Synthesis of the 111In-HpD-II complex in > 90% yield is achieved by a simple, rapid labeling method. Radiochemical purity and stability were verified by high-performance liquid chromatography. Using the canine model of intracerebral gliosarcoma, we followed the uptake of 111In-HpD-II in tumors with serial scintillation scanning. Localization of the tumor by 111In-HpD-II has been verified by contrast-enhanced computed tomographic scan followed by gross and histological examination of the enhancing brain region. Total body biodistribution of 111In-HpD-II at various times after injection has been evaluated. The ratio of uptake in tumor compared with surrounding brain peaked at 72 hours after injection. The knowledge of regional distribution and concentration of a photosensitizing agent within a tumor mass and surrounding brain allows for the most efficacious timing and localization of a photoactivating source.

UR - http://www.scopus.com/inward/record.url?scp=0024580204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024580204&partnerID=8YFLogxK

M3 - Article

C2 - 2523521

AN - SCOPUS:0024580204

VL - 24

SP - 547

EP - 556

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -